Severe Asthma

Patients with severe asthma achieved clinical remission based on a four-component definition with 52 weeks of mepolizumab, according to an abstract presented at the European Respiratory Society International Congress.

Mepolizumab, reslizumab and dupilumab were equally effective in controlling symptoms among patients with eosinophilic severe asthma, according to a study published in Annals of Allergy, Asthma & Immunology.

SAN DIEGO — A reimagined approach to uncontrolled severe asthma is needed amid poor diagnosis and management trends, according to Samuel Louie, MD, a professor of medicine at the University of California, Davis.

SAN ANTONIO — Patients with severe asthma and allergic rhinitis experienced fewer exacerbations after taking a biologic for 6 months, with greater decreases seen for biologics other than omalizumab, according to the CHRONICLE study.

SAN ANTONIO — Seventy percent of patients with severe eosinophilic asthma on mepolizumab for 5 to 6 years had no exacerbations for 1 year, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

In patients with severe, uncontrolled asthma, tezepelumab reduced the rate of asthma exacerbations and was tolerated for up to 2 years, according to an extension study published in The Lancet Respiratory Medicine.

The FDA has approved tezepelumab-ekko for self-administration in a prefilled, single-use pen among patients aged 12 years and older with severe asthma, according to a press release from the manufacturer.

Sensitization to Staphylococcal enterotoxin was correlated with type 2-high inflammation among children with moderate to severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.